Investment Thesis
Elutia faces critical fundamental challenges: revenue is declining 15% YoY while operating losses remain severe at -$6.3M on a $3.1M revenue base. Negative operating cash flow of -$7.8M creates a ~3.4 year cash runway, exacerbated by 1.16x debt/equity leverage and inability to cover interest from operations (coverage ratio: -4.8x).
Strengths
- Strong gross margin of 57.9% indicates underlying product value and pricing power
- Current liquidity position adequate with $28.5M cash and 2.05x current ratio providing near-term stability
- Biological products sector suggests potential for high-value pipeline despite early commercialization stage
Risks
- Revenue declining 15% YoY signals market adoption challenges or loss of product competitiveness
- Unsustainable operating losses (-$6.3M) with -203.9% operating margin on small revenue base
- Negative operating cash flow (-$7.8M) with approximately 3.4 year cash runway at current burn rate without profitability inflection
- High leverage (1.16x Debt/Equity) with negative interest coverage (-4.8x); cannot service debt from operational earnings
- Negative returns destroying shareholder value (ROE: -33.2%, ROA: -13.5%)
Key Metrics to Watch
- Quarterly revenue trajectory - must stabilize and inflect positive to avoid cash depletion scenario
- Operating expense reduction pathway - survival dependent on clear path to profitability before cash exhaustion
- Cash burn rate and runway - core survival metric for pre-profitable stage company
- Gross margin sustainability - whether 57.9% margin is maintainable as operations scale
Financial Metrics
Revenue
3.1M
Net Income
-7.5M
EPS (Diluted)
$-0.17
Free Cash Flow
-8.3M
Total Assets
55.2M
Cash
28.5M
Profitability Ratios
Gross Margin
57.9%
Operating Margin
-203.9%
Net Margin
-239.9%
ROE
-33.2%
ROA
-13.5%
FCF Margin
-266.2%
Balance Sheet & Liquidity
Current Ratio
2.05x
Quick Ratio
1.94x
Debt/Equity
1.16x
Debt/Assets
59.2%
Interest Coverage
-4.83x
Long-term Debt
26.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:04:46.277279 |
Data as of: 2026-03-31 |
Powered by Claude AI